1. Home
  2. IOBT vs ELTX Comparison

IOBT vs ELTX Comparison

Compare IOBT & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOBT
  • ELTX
  • Stock Information
  • Founded
  • IOBT 2014
  • ELTX 2011
  • Country
  • IOBT Denmark
  • ELTX United States
  • Employees
  • IOBT N/A
  • ELTX N/A
  • Industry
  • IOBT Biotechnology: Pharmaceutical Preparations
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IOBT Health Care
  • ELTX Health Care
  • Exchange
  • IOBT Nasdaq
  • ELTX Nasdaq
  • Market Cap
  • IOBT 59.3M
  • ELTX 54.6M
  • IPO Year
  • IOBT 2021
  • ELTX 2021
  • Fundamental
  • Price
  • IOBT $1.10
  • ELTX $8.54
  • Analyst Decision
  • IOBT Strong Buy
  • ELTX Strong Buy
  • Analyst Count
  • IOBT 3
  • ELTX 3
  • Target Price
  • IOBT $9.33
  • ELTX $9.50
  • AVG Volume (30 Days)
  • IOBT 120.7K
  • ELTX 59.7K
  • Earning Date
  • IOBT 03-04-2025
  • ELTX 03-28-2025
  • Dividend Yield
  • IOBT N/A
  • ELTX N/A
  • EPS Growth
  • IOBT N/A
  • ELTX N/A
  • EPS
  • IOBT N/A
  • ELTX N/A
  • Revenue
  • IOBT N/A
  • ELTX N/A
  • Revenue This Year
  • IOBT N/A
  • ELTX N/A
  • Revenue Next Year
  • IOBT N/A
  • ELTX N/A
  • P/E Ratio
  • IOBT N/A
  • ELTX N/A
  • Revenue Growth
  • IOBT N/A
  • ELTX N/A
  • 52 Week Low
  • IOBT $0.66
  • ELTX $3.34
  • 52 Week High
  • IOBT $1.85
  • ELTX $11.45
  • Technical
  • Relative Strength Index (RSI)
  • IOBT 68.67
  • ELTX 58.77
  • Support Level
  • IOBT $0.91
  • ELTX $7.78
  • Resistance Level
  • IOBT $1.14
  • ELTX $8.23
  • Average True Range (ATR)
  • IOBT 0.06
  • ELTX 0.60
  • MACD
  • IOBT 0.02
  • ELTX -0.15
  • Stochastic Oscillator
  • IOBT 87.13
  • ELTX 55.14

About IOBT IO Biotech Inc.

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: